NGNE
Neurogene·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NGNE
Neurogene Inc.
A biopharmaceutical company using protein design technology to develop immunotherapies
Biological Technology
12/26/2003
03/07/2014
NASDAQ Stock Exchange
107
12-31
Common stock
535 W 24th Street, 5th Floor, New York, NY 10011
--
Neurogene Inc., formerly known as 6175813 Canada Inc. (6175813 Canada Inc.). The company was incorporated on December 26, 2003 under the Canadian Business Corporations Act. Neurogene's mission is to treat devastating neurological diseases to improve the lives of patients and families affected by these rare diseases. Neurogene is developing new methods and treatments to address the limitations of traditional gene therapy in central nervous system diseases. This includes choosing a delivery method to maximize distribution to the target organization and designing the product to maximize potency and purity to achieve optimized efficacy and safety. Neurogene's new proprietary EXACT transgenic regulatory platform technology allows delivery of therapeutic levels while limiting transgenic toxicity associated with conventional gene therapy. Neurogene has built a state-of-the-art gene therapy manufacturing facility in Houston, Texas.
Company Financials
EPS
NGNE has released its 2025 Q3 earnings. EPS was reported at -0.99, versus the expected -1.09, beating expectations. The chart below visualizes how NGNE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
